JOHNSON & JOHNSON

Key metrics

Financial performance

Over the last 8 fiscal years JOHNSON & JOHNSON's revenue grew from $71.89B to $94.19B, a compound annual growth rate of 3.4%. Net profit margin expanded from 23.0% to 28.5% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (990 filings)

Recent press releases

• 2024 Health for Humanity Report2026-05-14

  Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

• Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter2026-05-12

  Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

• Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP2026-05-11

  Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

• Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference2026-05-11

  Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

• Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission2026-05-07

  Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Similar companies

The largest companies sharing JOHNSON & JOHNSON's SEC industry classification (pharmaceutical preparations).